Virtual heart model aims to predict and prevent HCM complications
NCT ID NCT07131371
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This study is developing a digital twin—a virtual model of the heart and blood vessels—to better understand and manage hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens. Researchers will gather detailed health data from 2500 people with HCM or the genetic mutation for it. The goal is to see if this virtual model can help predict who is at risk for serious problems like heart failure or sudden cardiac death, and guide more personalized care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Digital twin technology - a virtual model of the heart and blood vessels
- What this could lead to
- If successful, this could lead to more personalized and effective management of hypertrophic cardiomyopathy, potentially reducing risks of severe complications.
- What could go wrong
- The digital twin is an early-stage concept and may not accurately predict individual outcomes. The study is observational, so it won't directly test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCM - HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tampere university
Tampere, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.